# Topical Rapamycin/Sirolimus for Complicated Vascular Anomalies and Other Susceptible Lesions

> **NCT04172922** · PHASE1 · TERMINATED · sponsor: **Nemours Children's Clinic** · enrollment: 5 (actual)

## Conditions studied

- Vascular Anomaly

## Interventions

- **DRUG:** Topical Sirolimus

## Key facts

- **NCT ID:** NCT04172922
- **Lead sponsor:** Nemours Children's Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-04-01
- **Primary completion:** 2024-02-15
- **Final completion:** 2024-02-15
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** IRB suspended and subsequent early termination
- **Last updated:** 2025-12-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04172922

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04172922, "Topical Rapamycin/Sirolimus for Complicated Vascular Anomalies and Other Susceptible Lesions". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04172922. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*